Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
„Sopharma” AD (the Company) notifies that for April 2022 the Company recorded an increase in sales of 44% compared to the same month of the previous year, incl. 60% increase in domestic sales and 38% increase in export sales as a result of erratic recovery of activity in major foreign markets.
For the four months since the beginning of the year the revenues from sales of products increase by 34%, incl. 75% increase of sales for the domestic market and 10% increase in export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
Informacja dystrybuowana przez: pap-mediaroom.pl
